Open-label, single-center, clinical study evaluating the safety, tolerability and clinical effects of pentosan polysulfate sodium in subjects with mucopolysaccharidosis I
First published: 11 March 2024
https://onlinelibrary.wiley.com/doi/10.1002/jimd.12715
"Decreased GAG fragments and cartilage degradation biomarkers, and positive PROMIS outcomes support continued study of PPS as a potential disease-modifying treatment for MPS I with improved pain and function outcomes."
Open-label, single-center, clinical study evaluating the safety,...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.3¢ |
Change
0.013(5.68%) |
Mkt cap ! $78.70M | |||
| Open | High | Low | Value | Volume |
| 22.8¢ | 23.3¢ | 22.5¢ | $18.36K | 79.69K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 62862 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 190099 | 11 |
View Market Depth
| Last trade - 12.36pm 16/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |